PTGX Stock Overview
A biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Protagonist Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.50 |
| 52 Week High | US$43.76 |
| 52 Week Low | US$13.72 |
| Beta | 2.17 |
| 11 Month Change | 7.18% |
| 3 Month Change | 22.24% |
| 1 Year Change | 120.04% |
| 33 Year Change | -8.57% |
| 5 Year Change | 187.79% |
| Change since IPO | 254.70% |
Recent News & Updates
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Shareholder Returns
| PTGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.2% | -4.0% | -4.4% |
| 1Y | 120.0% | 12.5% | 19.1% |
Return vs Industry: PTGX exceeded the US Biotechs industry which returned 12.5% over the past year.
Return vs Market: PTGX exceeded the US Market which returned 19.1% over the past year.
Price Volatility
| PTGX volatility | |
|---|---|
| PTGX Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTGX's share price has been volatile over the past 3 months.
Volatility Over Time: PTGX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 125 | Dinesh Patel | www.protagonist-inc.com |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. Fundamentals Summary
| PTGX fundamental statistics | |
|---|---|
| Market cap | US$2.44b |
| Earnings (TTM) | US$169.95m |
| Revenue (TTM) | US$319.12m |
14.4x
P/E Ratio7.7x
P/S RatioIs PTGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTGX income statement (TTM) | |
|---|---|
| Revenue | US$319.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$319.12m |
| Other Expenses | US$149.17m |
| Earnings | US$169.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.89 |
| Gross Margin | 100.00% |
| Net Profit Margin | 53.26% |
| Debt/Equity Ratio | 0% |
How did PTGX perform over the long term?
See historical performance and comparison